Masimo Corp. (NASDAQ: MASI) reported Q2 EPS of $0.85, $0.04 better than the analyst estimate of $0.81. Revenue for the quarter came in at $301 million versus the consensus estimate of $289.73 million.

Q2 2020 Highlights

• Product revenue increased 31.1% to $301.0 million, or 32.0% on a constant currency basis;
• GAAP net income per diluted share was $0.96;
• Non-GAAP net income per diluted share was $0.85; and
• Shipments of noninvasive technology boards and instruments were a record 165,600.

Joe Kiani, Chairman and Chief Executive Officer of Masimo, said “I am incredibly proud of our team and how we continue to advance our mission to improve patient outcomes while reducing the cost of care, especially during this pandemic. From the beginning of the COVID-19 pandemic, we have done our best to support our customers as they have bravely been on the front lines of the worldwide response. Our unique ability to meet the needs of clinicians was in full view again this quarter as we reliably monitored their patients as only we could with unmatched reliability, accuracy and versatility, and launched multiple new products.”

For earnings history and earnings-related data on Masimo Corp. (MASI) click here.